AI Talks: Transforming the diagnosis of genetic disorders

In the context of the interactive activities organised by SKEL | The AI Lab, a talk took place from the company gMendel® with invited speaker Dr Christos Kyriakidis, Co-founder & CEO.

The talk titled Transforming the diagnosis of genetic disorders was held online on 29 September 2021, while a Q&A session followed the presentation.

Watch the session here:

Short bio: After completing a Ph.D. in Biochemistry (Crystallography), an M.Sc. in Physics and an MBA (Master of Business Administration), C. Kyriakidis has pursued a career in commercial functions in pharma and MedTech companies. His general management and business development skills were developed while running a $130 million international business and as a founder of a biosciences start-up company (sold in 2014). His marketing and project management skills were developed in an FMCG environment (L’Oréal), from where he moved to pharmaceutical/medical devices industry (Novo Nordisk, ALK, GN), including subsidiary (Brazil), regional (Asia, Eastern Europe, Latin America, Middle East & Africa) and global headquarter positions (Denmark). As a scientist, who moved to commercial operations, he takes every opportunity to search for and apply new methods, technologies, and approaches in the organizations where he works. Mr Kyriakidis has been a people leader for 20 years, developing multicultural diverse teams to reach their best potential through high engagement and has lived in 9 countries and done business in 60+ countries on all continents.

gMendel® is a Danish start-up aiming to transform the diagnosis of genetic disorders for better disease management. Despite continuous advances in genetic testing technology, accurate diagnosis and treatment remain a great challenge for patients, doctors, and healthcare systems. The current clinical protocol does not always provide an accurate diagnosis or a diagnosis at all, due to prohibitive costs of advanced technologies and scarce expert knowledge. The gMendel® approach is from diagnosis to treatment. Their transformative approach bridges the gap between new generation genomic tools and their clinical implementation, providing a shorter path to accurate diagnosis and potential treatment. This means reduced time and costs for patients and healthcare providers.

More News


Smart Attica EDIH at the “Innovation in Crete and the institutions that support it 3.0” conference
Smart Attica EDIH at Innovent Forum 2023
Smart Attica EDIH kicks off | Coordinated by ahedd, NCSR Demokritos
ahedd at the kick-off meeting of smartHEALTH EDIH
Smart Attica EDIH at “Innovation in Greece and the bodies that support it 4.0”
ahedd DIH at “Piraeus Business” conference
Tailor-made AI Workshops | AI Foundations – The AI Explorer
ahedd DIH at “Educating in Innovation” conference
ahedd DIH at the European Big Data Value Forum 2022
AI Industry Connect Talks: DeepSea